search
Found 154 results for Diabetes

Webinars

button
button

Videos

button
22 Nov

Managing Weight with Celevida

Celevida contains High Fibre and provides upto 3 hours satiety. It keeps you full and helps in managing weight.

button
22 Nov

What Makes Celevida Sweet?

Celevida contains Sucralose. It has no added sugar and safe to consume for Diabetics aswell

button

Courses

button
button
button

Medshorts

2Min Read
22 Feb

Efficacy and safety of bempedoic acid in patients with and without diabetes

A recent study demonstrated that bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and the risk of cardiovascular events in both Diabetic and non-diabetic patients .The findings of this study were published in the journal, Lancet. Diabetes & Endocrinology.

CLEAR Outcomes was a randomised, double-blind, placebo-controlled trial that included 13,970 patients, who were randomly assigned to those with diabetes (n=6373), prediabetes (n= 5796), and normoglycaemia (n=1801). Patients with or without cardiovascular disease who were unwilling or unable to adhere to the recommended doses of statins and an LDL cholesterol of 2·59 mmol/L or more were randomly assigned (1:1) to receive either bempedoic acid 180 mg once per day or placebo. Using the intention-to-treat population stratified by baseline glycaemia status, the efficacy endpoint of the prespecified analysis was a time-to-event analysis of four-component major adverse cardiovascular event (MACE-4), which is the composite of nonfatal myocardial infarction, cardiovascular death, nonfatal stroke, or coronary revascularisation. At baseline, the risk of new-onset diabetes and HbA1c increase was analysed in patients without diabetes.

After a median follow-up of 3.4 years, patients with diabetes had significant relative and absolute cardiovascular risk reductions in MACE-4 endpoints with bempedoic acid (absolute risk reduction of 2·4%) compared to the placebo. The incidence of new-onset diabetes was comparable in both the bempedoic acid and placebo groups. The HbA1c concentrations were similar between randomised groups in patients who had prediabetes and normoglycaemia, at 12 months and end of the study. Placebo-corrected LDL cholesterol concentrations and high-sensitivity C-reactive protein at 6 months showed reductions in each glycaemic stratum (diabetes, prediabetes, and normoglycemia) for patients who were randomly assigned to bempedoic acid.

It was observed that bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and the risk of cardiovascular events among patients with diabetes. With bempedoic acid, participants without diabetes had no increase in new-onset diabetes or worsening HbA1c. Based on the findings of this study, it can be concluded that the efficacy and cardiometabolic safety profile of bempedoic acid makes it a valuable clinical option for those with and without diabetes.

Efficacy and safety of bempedoic acid in patients with and without diabetes

A recent study demonstrated that bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and the risk of cardiovascular events in both Diabetic and non-diabetic patients .The findings of this study were published in the journal, Lancet. Diabetes & Endocrinology.

CLEAR Outcomes was a randomised, double-blind, placebo-controlled trial that included 13,970 patients, who were randomly assigned to those with diabetes (n=6373), prediabetes (n= 5796), and normoglycaemia (n=1801). Patients with or without cardiovascular disease who were unwilling or unable to adhere to the recommended doses of statins and an LDL cholesterol of 2·59 mmol/L or more were randomly assigned (1:1) to receive either bempedoic acid 180 mg once per day or placebo. Using the intention-to-treat population stratified by baseline glycaemia status, the efficacy endpoint of the prespecified analysis was a time-to-event analysis of four-component major adverse cardiovascular event (MACE-4), which is the composite of nonfatal myocardial infarction, cardiovascular death, nonfatal stroke, or coronary revascularisation. At baseline, the risk of new-onset diabetes and HbA1c increase was analysed in patients without diabetes.

After a median follow-up of 3.4 years, patients with diabetes had significant relative and absolute cardiovascular risk reductions in MACE-4 endpoints with bempedoic acid (absolute risk reduction of 2·4%) compared to the placebo. The incidence of new-onset diabetes was comparable in both the bempedoic acid and placebo groups. The HbA1c concentrations were similar between randomised groups in patients who had prediabetes and normoglycaemia, at 12 months and end of the study. Placebo-corrected LDL cholesterol concentrations and high-sensitivity C-reactive protein at 6 months showed reductions in each glycaemic stratum (diabetes, prediabetes, and normoglycemia) for patients who were randomly assigned to bempedoic acid.

It was observed that bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and the risk of cardiovascular events among patients with diabetes. With bempedoic acid, participants without diabetes had no increase in new-onset diabetes or worsening HbA1c. Based on the findings of this study, it can be concluded that the efficacy and cardiometabolic safety profile of bempedoic acid makes it a valuable clinical option for those with and without diabetes.

button
2Min Read
22 Feb

Efficacy and safety of bempedoic acid in patients with and without diabetes

A recent study demonstrated that bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and the risk of cardiovascular events in both Diabetic and non-diabetic patients .The findings of this study were published in the journal, Lancet. Diabetes & Endocrinology.

CLEAR Outcomes was a randomised, double-blind, placebo-controlled trial that included 13,970 patients, who were randomly assigned to those with diabetes (n=6373), prediabetes (n= 5796), and normoglycaemia (n=1801). Patients with or without cardiovascular disease who were unwilling or unable to adhere to the recommended doses of statins and an LDL cholesterol of 2·59 mmol/L or more were randomly assigned (1:1) to receive either bempedoic acid 180 mg once per day or placebo. Using the intention-to-treat population stratified by baseline glycaemia status, the efficacy endpoint of the prespecified analysis was a time-to-event analysis of four-component major adverse cardiovascular event (MACE-4), which is the composite of nonfatal myocardial infarction, cardiovascular death, nonfatal stroke, or coronary revascularisation. At baseline, the risk of new-onset diabetes and HbA1c increase was analysed in patients without diabetes.

After a median follow-up of 3.4 years, patients with diabetes had significant relative and absolute cardiovascular risk reductions in MACE-4 endpoints with bempedoic acid (absolute risk reduction of 2·4%) compared to the placebo. The incidence of new-onset diabetes was comparable in both the bempedoic acid and placebo groups. The HbA1c concentrations were similar between randomised groups in patients who had prediabetes and normoglycaemia, at 12 months and end of the study. Placebo-corrected LDL cholesterol concentrations and high-sensitivity C-reactive protein at 6 months showed reductions in each glycaemic stratum (diabetes, prediabetes, and normoglycemia) for patients who were randomly assigned to bempedoic acid.

It was observed that bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and the risk of cardiovascular events among patients with diabetes. With bempedoic acid, participants without diabetes had no increase in new-onset diabetes or worsening HbA1c. Based on the findings of this study, it can be concluded that the efficacy and cardiometabolic safety profile of bempedoic acid makes it a valuable clinical option for those with and without diabetes.

button
2Min Read
19 Feb

Continuous intrafemoral thrombolysis therapy improves diabetic foot ulcers and decreases cardiovascular events

A recent study found that long-term intrafemoral artery infusion of low-dose urokinase therapy improved diabetic foot ulcer (DFU) and decreased cardiovascular events in patients with DFUs. This study was published in the journal, BMJ Open Diabetes Research & Care.

This single-center, randomized, parallel study included 195 patients with DFU who were randomized either to continuous intrafemoral thrombolysis or conventional therapy groups. The first group received continuous intrafemoral urokinase injection for 7 days while the latter just received wound debridement and dressing change as part of the conventional group.  Subsequently, a follow-up of an average duration of 6.5 years was performed.

At the first month of intervention stage, it was found that in comparison with the conventional group, the ulcers achieved a significant improvement in continuous intrafemoral thrombolysis group which included an improved ulcer (27.6% vs 25.8%), a complete closure (72.4% vs 17.5%), and unchanged or impaired ulcer (0% vs 56.7%). Also, during the 6.5-year follow-up, the interventional group obtained a better complete healing rate for the primary outcome of ulcer closure rate. The secondary outcome of cardiovascular disease events showed a lower incidence with the continuous intrafemoral thrombolysis therapy, along with decreased incidence of cardiovascular death. Other than this, the therapy also improved local skin oxygenation and peripheral neuropathy as well as glycolipid metabolic profiles compared with the conventional therapy group.

From the above results, it can be concluded that better therapeutic efficacy to improve DFUs and decrease cardiovascular events may be possible with continuous intrafemoral thrombolysis therapy.

Continuous intrafemoral thrombolysis therapy improves diabetic foot ulcers and decreases cardiovascular events

A recent study found that long-term intrafemoral artery infusion of low-dose urokinase therapy improved diabetic foot ulcer (DFU) and decreased cardiovascular events in patients with DFUs. This study was published in the journal, BMJ Open Diabetes Research & Care.

This single-center, randomized, parallel study included 195 patients with DFU who were randomized either to continuous intrafemoral thrombolysis or conventional therapy groups. The first group received continuous intrafemoral urokinase injection for 7 days while the latter just received wound debridement and dressing change as part of the conventional group.  Subsequently, a follow-up of an average duration of 6.5 years was performed.

At the first month of intervention stage, it was found that in comparison with the conventional group, the ulcers achieved a significant improvement in continuous intrafemoral thrombolysis group which included an improved ulcer (27.6% vs 25.8%), a complete closure (72.4% vs 17.5%), and unchanged or impaired ulcer (0% vs 56.7%). Also, during the 6.5-year follow-up, the interventional group obtained a better complete healing rate for the primary outcome of ulcer closure rate. The secondary outcome of cardiovascular disease events showed a lower incidence with the continuous intrafemoral thrombolysis therapy, along with decreased incidence of cardiovascular death. Other than this, the therapy also improved local skin oxygenation and peripheral neuropathy as well as glycolipid metabolic profiles compared with the conventional therapy group.

From the above results, it can be concluded that better therapeutic efficacy to improve DFUs and decrease cardiovascular events may be possible with continuous intrafemoral thrombolysis therapy.

button
2Min Read
19 Feb

Continuous intrafemoral thrombolysis therapy improves diabetic foot ulcers and decreases cardiovascular events

A recent study found that long-term intrafemoral artery infusion of low-dose urokinase therapy improved diabetic foot ulcer (DFU) and decreased cardiovascular events in patients with DFUs. This study was published in the journal, BMJ Open Diabetes Research & Care.

This single-center, randomized, parallel study included 195 patients with DFU who were randomized either to continuous intrafemoral thrombolysis or conventional therapy groups. The first group received continuous intrafemoral urokinase injection for 7 days while the latter just received wound debridement and dressing change as part of the conventional group.  Subsequently, a follow-up of an average duration of 6.5 years was performed.

At the first month of intervention stage, it was found that in comparison with the conventional group, the ulcers achieved a significant improvement in continuous intrafemoral thrombolysis group which included an improved ulcer (27.6% vs 25.8%), a complete closure (72.4% vs 17.5%), and unchanged or impaired ulcer (0% vs 56.7%). Also, during the 6.5-year follow-up, the interventional group obtained a better complete healing rate for the primary outcome of ulcer closure rate. The secondary outcome of cardiovascular disease events showed a lower incidence with the continuous intrafemoral thrombolysis therapy, along with decreased incidence of cardiovascular death. Other than this, the therapy also improved local skin oxygenation and peripheral neuropathy as well as glycolipid metabolic profiles compared with the conventional therapy group.

From the above results, it can be concluded that better therapeutic efficacy to improve DFUs and decrease cardiovascular events may be possible with continuous intrafemoral thrombolysis therapy.

button
2Min Read
31 Jan

Tirzepatide reduces the predicted risk of developing type 2 diabetes in obese people

A recent study suggests that tirzepatide therapy demonstrated a decrease in the predicted 10-year risk of developing type 2 diabetes (T2D) when compared to placebo among individuals, who were either obese or overweight. The study’s findings were published in the journal, Diabetes, obesity & metabolism.

In the post hoc analysis study of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was utilized to calculate the predicted  10-year risk of T2D at baseline, week 24, and week 72 among participants who were randomized to receive either 5, 10, or 15 mg tirzepatide or placebo. The mean changes in risk scores from baseline to weeks 24 and 72 were compared between the tirzepatide and placebo groups. The participants' glycaemic status and body mass index at baseline were used to conduct subgroup analyses.

At week 72, the tirzepatide groups demonstrated significantly higher reductions in mean absolute T2D predicted risk scores : 5 mg (12.4%), 10 mg (14.4%), and 15 mg (14.7%) when compared to the placebo group (0.7%). Participants with and without prediabetes experienced significantly greater risk reductions in the tirzepatide groups compared to the placebo group. Participants with prediabetes (range: 16.0%- 20.3%) had greater mean risk score reductions from baseline compared to those without prediabetes (range: 10.1% -11.3%). Additionally, across different body mass index subgroups, the tirzepatide groups exhibited significantly higher mean reductions from baseline compared to the placebo group.

To summarize, tirzepatide demonstrated a substantial decrease in the predicted 10-year risk of developing type 2 diabetes (T2D) when compared to a placebo in individuals with obesity or overweight, irrespective of their baseline glycemic status.

Tirzepatide reduces the predicted risk of developing type 2 diabetes in obese people

A recent study suggests that tirzepatide therapy demonstrated a decrease in the predicted 10-year risk of developing type 2 diabetes (T2D) when compared to placebo among individuals, who were either obese or overweight. The study’s findings were published in the journal, Diabetes, obesity & metabolism.

In the post hoc analysis study of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was utilized to calculate the predicted  10-year risk of T2D at baseline, week 24, and week 72 among participants who were randomized to receive either 5, 10, or 15 mg tirzepatide or placebo. The mean changes in risk scores from baseline to weeks 24 and 72 were compared between the tirzepatide and placebo groups. The participants' glycaemic status and body mass index at baseline were used to conduct subgroup analyses.

At week 72, the tirzepatide groups demonstrated significantly higher reductions in mean absolute T2D predicted risk scores : 5 mg (12.4%), 10 mg (14.4%), and 15 mg (14.7%) when compared to the placebo group (0.7%). Participants with and without prediabetes experienced significantly greater risk reductions in the tirzepatide groups compared to the placebo group. Participants with prediabetes (range: 16.0%- 20.3%) had greater mean risk score reductions from baseline compared to those without prediabetes (range: 10.1% -11.3%). Additionally, across different body mass index subgroups, the tirzepatide groups exhibited significantly higher mean reductions from baseline compared to the placebo group.

To summarize, tirzepatide demonstrated a substantial decrease in the predicted 10-year risk of developing type 2 diabetes (T2D) when compared to a placebo in individuals with obesity or overweight, irrespective of their baseline glycemic status.

button
2Min Read
31 Jan

Tirzepatide reduces the predicted risk of developing type 2 diabetes in obese people

A recent study suggests that tirzepatide therapy demonstrated a decrease in the predicted 10-year risk of developing type 2 diabetes (T2D) when compared to placebo among individuals, who were either obese or overweight. The study’s findings were published in the journal, Diabetes, obesity & metabolism.

In the post hoc analysis study of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was utilized to calculate the predicted  10-year risk of T2D at baseline, week 24, and week 72 among participants who were randomized to receive either 5, 10, or 15 mg tirzepatide or placebo. The mean changes in risk scores from baseline to weeks 24 and 72 were compared between the tirzepatide and placebo groups. The participants' glycaemic status and body mass index at baseline were used to conduct subgroup analyses.

At week 72, the tirzepatide groups demonstrated significantly higher reductions in mean absolute T2D predicted risk scores : 5 mg (12.4%), 10 mg (14.4%), and 15 mg (14.7%) when compared to the placebo group (0.7%). Participants with and without prediabetes experienced significantly greater risk reductions in the tirzepatide groups compared to the placebo group. Participants with prediabetes (range: 16.0%- 20.3%) had greater mean risk score reductions from baseline compared to those without prediabetes (range: 10.1% -11.3%). Additionally, across different body mass index subgroups, the tirzepatide groups exhibited significantly higher mean reductions from baseline compared to the placebo group.

To summarize, tirzepatide demonstrated a substantial decrease in the predicted 10-year risk of developing type 2 diabetes (T2D) when compared to a placebo in individuals with obesity or overweight, irrespective of their baseline glycemic status.

button